Actively Recruiting

Age: 65Years +
All Genders
NCT05801380

Monitoring Drug Efficacy in Patients with Alzheimer's Disease

Led by University of the Philippines · Updated on 2025-01-07

60

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will explore the different factors associated with drug response to acetylcholinesterase (AChE) inhibitor (donepezil) and NMDA receptor antagonist (memantine) in patients with Alzheimer's Disease.

CONDITIONS

Official Title

Monitoring Drug Efficacy in Patients with Alzheimer's Disease

Who Can Participate

Age: 65Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Newly diagnosed with mild or moderate dementia using the Montreal Cognitive Assessment and Clinical Dementia Rating performed by a licensed psychometrician
  • Clinically diagnosed by an expert adult neurologist as having probable Alzheimer's Disease using NINCDS-ADRDA criteria
  • Treatment naive for acetylcholinesterase inhibitors or memantine, or not taken these drugs in the last 3 months except for adverse drug reaction
  • Age 65 years old or older
  • Residing in the National Capital Region
  • Able to read and understand written and spoken English and Filipino
Not Eligible

You will not qualify if you...

  • Structural or vascular causes of dementia other than subcortical lacunes (2 or less) seen in plain CT scan
  • Dementia diagnosis other than Alzheimer's Disease as determined by an expert neurologist
  • Untreated depression or related psychiatric disorders in the last 6 months
  • Use of systemic antibiotics in the previous 3 months before providing fecal specimens
  • Use of corticosteroids, immune stimulating medications, or immunosuppressive agents within past 2 weeks or regularly for immune disorders
  • Use of proton-pump inhibitors, H2-receptor antagonists, tricyclic antidepressants, narcotics, anticholinergic medications, laxatives, or anti-diarrheal in past 4 weeks
  • Consumption of large doses of commercial probiotics (≥108 cfu per day)
  • Major dietary change during previous month
  • Major gastrointestinal surgery in past 5 years except cholecystectomy and appendectomy
  • Major bowel resection at any time
  • Active uncontrolled gastrointestinal disorders or diseases including inflammatory bowel disease, indeterminate colitis, irritable bowel syndrome, persistent infectious gastroenteritis, colitis or gastritis, chronic diarrhea of unknown cause, recurrent Clostridium difficile infection, untreated Helicobacter pylori infection, chronic constipation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Philippine General Hospital

Manila, National Capital Region, Philippines, 1000

Actively Recruiting

Loading map...

Research Team

F

Fresthel Monica M Climacosa, MD, PhD

CONTACT

V

Veeda Michelle M Anlacan, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here